MedTrace Logo

Ticagrelore Alone Post PCI

NCT06509893 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5400

Last updated 2025-05-21

No results posted yet for this study

Summary

After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in registry of professor Kojuri cardiology clinic

Conditions

Interventions

DRUG

aspirin 80 mg and clopidogrel 75 mg daily

post PCI patients received these two drugs as dual antiplatelet regimen

DRUG

Ticagrelor 90 MG

Post PCI patients receive Ticagrelor 90 mg two times daily as single potent antiplatelet

Sponsors & Collaborators

  • Shiraz University of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2025-12-01
Completion
2026-05-01

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06509893 on ClinicalTrials.gov